X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
0
Listed Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Under the agreement, Teva will use Closed Loop Medicine’s proprietary SaMD platform which advances the development of personalised medicines, including CLM-HT01 (amlodipine), in patients with chronic disorders by combining dose-optimised drug therapy with digital care.
Lead Product(s): Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CLM-HT01
Highest Development Status: N/AProduct Type: Small molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 26, 2024
Details:
GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).
Lead Product(s): Bisoprolol Fumarate,Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Biramlo
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Midas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 19, 2022
Details:
The agreement outlines a transition period during which Daiichi Sankyo and Cosette will transfer responsibilities for the manufacture and commercialization of Azor, Benicar, Effient and other products, including quality assurance, pharmacovigilance and regulatory matters.
Lead Product(s): Amlodipine,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Azor
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment January 18, 2022
Details:
GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
Details:
Pfizer and Mylan have received clearance from the US FTC to advance the merger of Pfizer’s Upjohn generics unit and Mylan. As part of the FTC clearance, the companies need to divest seven products before moving forward with the merger, this includes Upjohn’s Caduet.
Lead Product(s): Amlodipine,Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Caduet
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: $12,000.0 million Upfront Cash: Undisclosed
Deal Type: Merger November 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
